Stephanie Ann Haller

Ms. Haller joined Anokion in 2022 as Senior Vice President, Clinical Operations. Stephanie brings extensive experience in the strategic planning and execution of phase 1-4 clinical trials. She has helped direct clinical research activities across numerous early and late-stage clinical trials in the last decade. Most recently Ms. Haller served as Vice President, Clinical Operations at Alexion Pharmaceuticals following that company’s acquisition of Syntimmune. While at Alexion/Syntimmune, Ms. Haller served as clinical operations therapeutic area lead for nephrology and FcRn franchise lead. Prior to this, Ms. Haller was Vice President, Clinical Operations at Dimension Therapeutics. While at Dimension she was instrumental in the successful clinical evaluation of multiple gene therapy assets, contributing to the acquisition of the company by Ultragenyx. Prior to Dimension, Ms. Haller served as Director, Clinical Programs at Shire plc, where she oversaw global clinical development plans for early-phase, rare disease assets. Earlier in her career, Stephanie held positions of increasing responsibility at Halloran Consulting Group, Genzyme Corporation, Muro Pharmaceuticals, and ICON Clinical Research. She earned a B.A. in Psychology from Denison University and an M.S. in Experimental Psychology from Villanova University.